{"title":"精神分裂症门诊患者使用仓库抗精神病药的随访研究","authors":"Joachim Tegeler, Erlo Lehmann","doi":"10.1016/0364-7722(81)90008-4","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>1.</span><span><p>1. In the last years many studies have demonstrated that the maintenance therapy with depot-neuroleptics could reduce the readmissions of schizophrenic outpatients in comparison to short-acting medication.</p></span></li><li><span>2.</span><span><p>2. Most placebo-controlled studies are based on a follow-up of only one or two years. In a “mirror-image” study over 5 years the relapse rates and the duration of the hospital stay of 78 schizophrenic outpatients treated with depot-neuroleptics were compared with these parameters under short-acting medication.</p></span></li><li><span>3.</span><span><p>3. There was a high significant reduction of the readmissions rate and of the inpatient time under the treatment with depot-neuroleptics.</p></span></li><li><span>4.</span><span><p>4. The demographic data and therapeutic conditions which influence these results were discussed.</p></span></li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":"5 1","pages":"Pages 79-90"},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90008-4","citationCount":"16","resultStr":"{\"title\":\"A follow-up study of schizophrenic outpatients treated with depot-neuroleptics\",\"authors\":\"Joachim Tegeler, Erlo Lehmann\",\"doi\":\"10.1016/0364-7722(81)90008-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>1.</span><span><p>1. In the last years many studies have demonstrated that the maintenance therapy with depot-neuroleptics could reduce the readmissions of schizophrenic outpatients in comparison to short-acting medication.</p></span></li><li><span>2.</span><span><p>2. Most placebo-controlled studies are based on a follow-up of only one or two years. In a “mirror-image” study over 5 years the relapse rates and the duration of the hospital stay of 78 schizophrenic outpatients treated with depot-neuroleptics were compared with these parameters under short-acting medication.</p></span></li><li><span>3.</span><span><p>3. There was a high significant reduction of the readmissions rate and of the inpatient time under the treatment with depot-neuroleptics.</p></span></li><li><span>4.</span><span><p>4. The demographic data and therapeutic conditions which influence these results were discussed.</p></span></li></ul></div>\",\"PeriodicalId\":20801,\"journal\":{\"name\":\"Progress in neuro-psychopharmacology\",\"volume\":\"5 1\",\"pages\":\"Pages 79-90\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0364-7722(81)90008-4\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in neuro-psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0364772281900084\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neuro-psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0364772281900084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A follow-up study of schizophrenic outpatients treated with depot-neuroleptics
1.
1. In the last years many studies have demonstrated that the maintenance therapy with depot-neuroleptics could reduce the readmissions of schizophrenic outpatients in comparison to short-acting medication.
2.
2. Most placebo-controlled studies are based on a follow-up of only one or two years. In a “mirror-image” study over 5 years the relapse rates and the duration of the hospital stay of 78 schizophrenic outpatients treated with depot-neuroleptics were compared with these parameters under short-acting medication.
3.
3. There was a high significant reduction of the readmissions rate and of the inpatient time under the treatment with depot-neuroleptics.
4.
4. The demographic data and therapeutic conditions which influence these results were discussed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
